Cargando…

Synergy of therapeutic vaccination against HPV16 oncogenic proteins and standard chemotherapeutics

Detalles Bibliográficos
Autores principales:	Melief, Cornelis J, Welters, Marij JP, van der Sluis, Tetje, van Meir, Helene, van Duikeren, Suzanne, Huppelschoten, Suzanna, Jordanova, Ekaterina S, Kroep, Judith, Kenter, Gemma, Smit, Vincent, Ossendorp, Ferry, van de Water, Bob, van Poelgeest, Mariette, Burggraaf, Jacobus, Arens, Ramon, van der Burg, Sjoerd H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288697/ http://dx.doi.org/10.1186/2051-1426-2-S3-P56

Ejemplares similares

Synergy between chemotherapy and cancer vaccination
por: van der Sluis, Tetje C., et al.
Publicado: (2015)

Delayed vaccine-induced CD8(+) T cell expansion by topoisomerase I inhibition mediates enhanced CD70-dependent tumor eradication
por: van der Sluis, Tetje C, et al.
Publicado: (2023)

Interleukin‐6‐mediated resistance to immunotherapy is linked to impaired myeloid cell function
por: Beyranvand Nejad, Elham, et al.
Publicado: (2020)

Detection and functional assessment of regulatory T cells in clinical samples
por: Santegoets, Saskia, et al.
Publicado: (2014)

Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients
por: van Meir, H., et al.
Publicado: (2016)

Pre-existing inflammatory immune microenvironment predicts the clinical response of vulvar high-grade squamous intraepithelial lesions to therapeutic HPV16 vaccination
por: Abdulrahman, Ziena, et al.
Publicado: (2020)

The Tumor Microenvironment and Immunotherapy of Oropharyngeal Squamous Cell Carcinoma
por: Welters, Marij J. P., et al.
Publicado: (2020)

A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer
por: Dijkgraaf, Eveline M., et al.
Publicado: (2015)

A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions
por: de Vos van Steenwijk, Peggy J., et al.
Publicado: (2012)

Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions
por: Speetjens, Frank M, et al.
Publicado: (2022)

Inhibition of CSF-1R Supports T-Cell Mediated Melanoma Therapy
por: Sluijter, Marjolein, et al.
Publicado: (2014)

Monitoring of the Immune Dysfunction in Cancer Patients
por: Santegoets, Saskia J. A. M., et al.
Publicado: (2016)

The combined HPV16-E2/E6/E7 T cell response in oropharyngeal cancer predicts superior survival
por: Santegoets, Saskia J., et al.
Publicado: (2023)

HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial
por: van Poelgeest, Mariette I E, et al.
Publicado: (2013)

Lack of myeloid cell infiltration as an acquired resistance strategy to immunotherapy
por: Beyranvand Nejad, Elham, et al.
Publicado: (2020)

The Breadth of Synthetic Long Peptide Vaccine-Induced CD8(+) T Cell Responses Determines the Efficacy against Mouse Cytomegalovirus Infection
por: Panagioti, Eleni, et al.
Publicado: (2016)

Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer
por: Wouters, MCA, et al.
Publicado: (2015)

Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication
por: Zom, Gijs G., et al.
Publicado: (2018)

High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status
por: Kortekaas, Kim E., et al.
Publicado: (2019)

TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients
por: Zom, Gijs G., et al.
Publicado: (2016)

PROTECT: Prospective Phase-II-Trial Evaluating Adaptive Proton Therapy for Cervical Cancer to Reduce the Impact on Morbidity and the Immune System
por: Corbeau, Anouk, et al.
Publicado: (2021)

A poly-neoantigen DNA vaccine synergizes with PD-1 blockade to induce T cell-mediated tumor control
por: Tondini, Elena, et al.
Publicado: (2019)

CD161 expression and regulation defines rapidly responding effector CD4+ T cells associated with improved survival in HPV16-associated tumors
por: Duurland, Chantal L, et al.
Publicado: (2022)

Potential use of lymph node-derived HPV-specific T cells for adoptive cell therapy of cervical cancer
por: van Poelgeest, Mariëtte I. E., et al.
Publicado: (2016)

Cell mediated immunity against HPV16 E2, E6 and E7 peptides in women with incident CIN and in constantly HPV-negative women followed-up for 10-years
por: Paaso, Anna, et al.
Publicado: (2015)

PD-L1 blockade engages tumor-infiltrating lymphocytes to co-express targetable activating and inhibitory receptors
por: Beyrend, Guillaume, et al.
Publicado: (2019)

Human Papillary and Reticular Fibroblasts Show Distinct Functions on Tumor Behavior in 3D-Organotypic Cultures Mimicking Melanoma and HNSCC
por: Wu, Shidi, et al.
Publicado: (2022)

Local immunomodulation for cancer therapy: Providing treatment where needed
por: Fransen, Marieke F, et al.
Publicado: (2013)

Human papillomavirus 16-specific cell-mediated immunity in children born to mothers with incident cervical intraepithelial neoplasia (CIN) and to those constantly HPV negative
por: Koskimaa, Hanna-Mari, et al.
Publicado: (2015)

Dominant Antiviral CD8(+) T Cell Responses Empower Prophylactic Antibody-Eliciting Vaccines Against Cytomegalovirus
por: Pardieck, Iris N., et al.
Publicado: (2022)

Predicting the efficacy of cancer vaccines by evaluating T-cell responses
por: van Duikeren, Suzanne, et al.
Publicado: (2013)

The simultaneous ex vivo detection of low-frequency antigen-specific CD4+ and CD8+ T-cell responses using overlapping peptide pools
por: Singh, Satwinder Kaur, et al.
Publicado: (2012)

CD163(+) cytokine-producing cDC2 stimulate intratumoral type 1 T cell responses in HPV16-induced oropharyngeal cancer
por: Santegoets, Saskia J, et al.
Publicado: (2020)

Standard radiotherapy but not chemotherapy impairs systemic immunity in non-small cell lung cancer
por: Talebian Yazdi, Mehrdad, et al.
Publicado: (2016)

Short-Term Fasting Synergizes with Solid Cancer Therapy by Boosting Antitumor Immunity
por: de Gruil, Nadia, et al.
Publicado: (2022)

Harmonization of the intracellular cytokine staining assay
por: Welters, Marij J. P., et al.
Publicado: (2012)

Interferon‐γ and IL‐5 associated cell‐mediated immune responses to HPV16 E2 and E6 distinguish between persistent oral HPV16 infections and noninfected mucosa
por: Paaso, Anna, et al.
Publicado: (2021)

A third vaccination with a single T cell epitope confers protection in a murine model of SARS-CoV-2 infection
por: Pardieck, Iris N., et al.
Publicado: (2022)

Enforced OX40 Stimulation Empowers Booster Vaccines to Induce Effective CD4(+) and CD8(+) T Cell Responses against Mouse Cytomegalovirus Infection
por: Panagioti, Eleni, et al.
Publicado: (2017)

Human papillomavirus 16 E2-, E6- and E7-specific T-cell responses in children and their mothers who developed incident cervical intraepithelial neoplasia during a 14-year follow-up of the Finnish Family HPV cohort
por: Koskimaa, Hanna-Mari, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_i6kdqn6blkcbaacqe3icg82d2f